Skip to main content
Finanzoo GmbH Finanzoo GmbH

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313
Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


How The Titan XT Cycle Is Rewriting The Omnicell (OMCL) Investment Story

2026-03-05
Omnicell’s updated analyst narrative keeps the modeled fair value steady at US$57.43, even as some price targets are being revised in different directions. On one side, bullish analysts point to the Titan XT cabinet lineup and a potential replacement cycle as reasons to lift targets; more cautious voices are trimming theirs based on timing and execution risks around that same story. As you read on, you will see how these opposing calls shape the evolving case for following Omnicell from...
Yahoo

Will Strong Q4 Beat and Software Pivot Change Omnicell's (OMCL) Investment Narrative?

2026-03-05
Omnicell recently reported Q4 2025 results that exceeded its own guidance across revenue, product bookings, and annual recurring revenue, while launching the Titan XT system to extend intelligent medication management into nursing care areas. Alongside this, the company is accelerating a shift from hardware-centric sales toward software, services, and acquisitions such as ANiGENT, aiming to build a larger base of recurring, healthcare IT–style revenue. Now we’ll examine how Omnicell’s...
Yahoo

3 Reasons to Avoid OMCL and 1 Stock to Buy Instead

2026-03-03
Over the past six months, Omnicell has been a great trade, beating the S&P 500 by 19.8%. Its stock price has climbed to $41.48, representing a healthy 26.4% increase. This performance may have investors wondering how to approach the situation.
Yahoo

Omnicell, Inc. (OMCL): A Bull Case Theory

2026-02-28
We came across a bullish thesis on Omnicell, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on OMCL. Omnicell, Inc.’s share was trading at $38.61 as of February 18th. OMCL’s trailing P/E was 912.50 according to Yahoo Finance. Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. OMCL is positioning itself […]
Yahoo

3 Cash-Producing Stocks We Find Risky

2026-02-26
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Yahoo

Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know

2026-02-23
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to
Yahoo

Omnicell (OMCL) Is Down 19.0% After Profit Squeeze Despite Solid 2026 Revenue Outlook - What's Changed

2026-02-12
In early February 2026, Omnicell reported fourth-quarter 2025 revenue of US$313.98 million with a small net loss of US$2.03 million, and issued first-quarter 2026 revenue guidance of US$300 million to US$310 million plus full-year 2026 guidance of US$1.22 billion to US$1.26 billion. The results highlighted pressure on profitability despite revenue growth, even as management pointed to strong demand for XT S10 devices and a multi-year Titan XT refresh opportunity exceeding US$2.50 billion. We...
Yahoo

The Top 5 Analyst Questions From Omnicell’s Q4 Earnings Call

2026-02-12
Omnicell’s fourth quarter was met with a significant negative market reaction, as the company delivered revenue in line with Wall Street expectations but posted a notable shortfall in non-GAAP profitability. Management attributed the quarter’s performance to robust demand for its point-of-care connected devices, particularly the XT S10, and highlighted strong annual recurring revenue momentum. However, mix shifts in product and customer base, as well as higher operating costs tied to new product
Yahoo

Omnicell, Inc. 2025 Q4 - Results - Earnings Call Presentation

2026-02-08
2026-02-08. The following slide deck was published by Omnicell, Inc.
SeekingAlpha

Piper Sandler Reiterates Overweight on Omnicell, Lowers Price Target to $49

2026-02-06
Piper Sandler analyst Jessica Tassan reiterates Omnicell (NASDAQ:OMCL) with a Overweight and lowers the price target from $63 to $49.
Benzinga